Dysport phase III study results in children with cerebral palsy

Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the scientific journal Pediatrics published the detailed results of the phase III randomized study (NCT01249417) showing both the efficacy and the safety of Dysport® in the treatment of  dynamic equinus foot deformity (also known as pediatric lower limb spasticity), a condition associated with cerebral palsy in children.

See the full article here:


Leave a Reply